SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir $PLTR is trending amid news of a $448M Navy contract for its ShipOS AI platform, intended to modernize submarine maintenance. Community discussions revolve around the potential impact on revenue and global expansion, with some questioning the valuation and others remaining strongly bullish. Broader conversations touch on Palantir's growing presence in corporate America and the implications of government contracts.

Aimei Health Technology Co., Ltd. is a blank check company, which engages in entering a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses. The company was founded on April 27, 2023 and is headquartered in New York, NY.

Aimei Health Technology Co Ltd

Aimei Health Technology ($AFJK) is trending due to a massive intraday surge, reportedly driven by social media and chat room momentum. Traders are discussing the potential for continued gains, while also pointing out the risks associated with the stock's volatility and low float. Some users are comparing it to other high-flying stocks, while others suggest caution due to its two-employee structure and potential for a pump-and-dump.

Motorola Solutions, Inc. engages in the provision of communication infrastructure, devices, accessories, software, and services. It operates through the Products and Systems Integration and Software and Services segments. The Products and Systems Integration segment includes a portfolio of infrastructure, devices, accessories, and video security devices, and the implementation and integration of such systems, devices, and applications. The Software and Services segment focuses on the public safety and enterprise Command Center Software, unified communications applications, and video software solutions. The company was founded on September 25, 1928 and is headquartered in Chicago, IL.

Motorola Solutions Inc

MSI is trending due to mixed sentiment after its earnings report, with some traders pointing to institutions adding put protection despite accumulating shares. The community is debating whether the stock is oversold and poised for a reversal, while others cite large dark pool prints and potential accumulation as bullish signals. Upgrades from analysts may also be contributing to the increased attention on the stock.

Oriental Culture Holding Ltd. operates as a holding company, which is engaged in providing collectibles and artwork e-commerce services through its subsidiaries. The firm facilitates trading by individual customers of all kinds of collectibles, artwork, and certain commodities on its online platform owned by its subsidiary in Hong Kong, namely the China International Assets and Equity of Artworks Exchange Limited. It provides services including investor education, market information, customer support, and technology infrastructure. The company was founded in March 2018 and is headquartered in Hong Kong.

Oriental Culture Holding Ltd

Oriental Culture Holding is trending due to a massive surge in price and trading volume, with community members citing early alerts from specific users and comparing it to other recent high-percentage runners. Traders are actively discussing entry and exit points, as well as overnight price action, while also speculating about the company's fundamentals and potential for further gains. The stock's movement is also drawing attention as part of a broader trend involving Hong Kong-based stocks experiencing significant volatility.

Enveric Biosciences, Inc. is a biotechnology company which engages in the development of neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company was founded on February 28, 1994 and is headquartered in Cambridge, MA.

Enveric Biosciences Inc

Enveric Biosciences is trending due to recent attention on its low float and potential for a short squeeze, with some traders drawing comparisons to other high-momentum stocks. Community members are discussing the company's intellectual property and ongoing patent litigation related to AbbVie's acquisition, speculating on a possible settlement. The stock's volatile history, including reverse splits and public offerings, is also a key point of discussion among investors.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending amid speculation about a potential deal with Warner Bros. Discovery, with community chatter focusing on a possible bidding war with Paramount and the deal's potential impact. Some traders believe the stock is oversold and due for a bounce, while others express concern about the financial implications of acquiring WBD and the potential for regulatory hurdles.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

SLV is trending as silver reaches new highs, driven by potential supply squeezes and increasing industrial demand. Community discussions revolve around whether the current momentum is sustainable, with some traders considering short positions while others remain bullish, citing silver's undervaluation and potential for further gains. The broader context includes silver's role in technology, green energy, and its historical relationship with gold, all contributing to the heightened interest.

Vor Biopharma, Inc. engages in developing cell therapies for treating cancer. It is a clinical-stage cell therapy company that combines a novel patient engineering approach with therapies to provide a single company solution for patients suffering from hematological malignancies. The company was founded by Aleks Radovic-Moreno and Siddhartha Mukherjee on December 30, 2015 and is headquartered in Boston, MA.

Vor Biopharma Inc

VOR is trending as community members discuss its potential after JP Morgan initiated coverage with an overweight rating and a $43 price target. Some traders believe VOR is primed for a short squeeze, while others point to high trading volume and potential catalysts from its pipeline. Discussions also focus on the company's recent acquisition of telitacicept and upcoming clinical milestones.

AeroVironment, Inc. engages in the design, development, and production of multi-domain robotic systems and related services for government agencies and businesses. It operates through the following business segments: UnCrewed Systems, Loitering Munitions Systems, and MacCready Work. The UnCrewed Systems segment focuses primarily on small UAS products designed to operate reliably at lower altitudes in a wide range of environmental conditions. The Loitering Munitions Systems segment focuses primarily on tube-launched aircraft that deploy with the push of a button, fly at higher speeds than small UAS products, and perform either effects delivery or reconnaissance missions, and related support services including training, spare parts, product repair, and product replacement. The MacCready Works segment focuses on customer-funded research and development in the areas of HAPS, robotics, sensors, software analytics, data intelligence, and connectivity. The company was founded by Paul B. MacCready, Jr. in July 1971 and is headquartered in Arlington, VA.

AeroVironment Inc.

AeroVironment ($AVAV) is trending amid mixed reactions to its latest earnings report, which featured a revenue beat but an EPS miss, alongside raised full-year earnings guidance. The community is actively debating the company's growth prospects, margin performance, and the potential impact of defense spending trends. Bullish sentiment is fueled by strong revenue growth and significant contract wins, while bears point to margin concerns and government guidance.

Horizon Space Acquisition I Corp. operates as a blank check company. It was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company was founded on June 14, 2022 and is headquartered in New York, NY.

Horizon Space Acquisition I Corp

Horizon Space Acquisition I Corp (HSPO) is trending due to a massive volume spike and price surge, driven by its announcement of voluntary delisting from the Nasdaq. The community is actively discussing potential short squeezes and comparing it to other high-flying, low-float stocks, while also cautioning about the risks associated with a delisting company.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Manufacturing Stocks To Keep An Eye On - December 9th

Taiwan Semiconductor Manufacturing, Applied Materials, and Vor Biopharma are the three Manufacturing stocks to watch today, according to MarketBeat's stock screener tool. Manufacturing stocks are...

Vor Biopharma (NASDAQ:VOR) Now Covered by Analysts at JPMorgan Chase & Co.

JPMorgan Chase & Co. started coverage on Vor Biopharma in a research report on Tuesday. They set an "overweight" rating and a $43.00 price objective for the company...

<ul class="summary-bullets"><li>Vor Biopharma shares surged over&nbsp;40%&nbsp;after JPMorgan initiated coverage of the company.&nbsp;</li><li>JPMorgan’s bullish stance comes amid Phase 3 clinical trial success for an autoimmune drug, telitacicept.&nbsp;</li><li>On Stocktwits, retail sentiment around the stock jumped to ‘extremely bullish’ while message volume rose to ‘extremely high’ levels.</li></ul>Shares of Vor Biopharma Inc. (VOR) rallied over 40% on Tuesday in premarket trading after JPMorgan initiated coverage of the clinical-stage biopharma company with a bullish stance.&nbsp;In a note on Tuesday, as cited by TheFly, JPMorgan awarded&nbsp;<a href="https://stocktwits.com/symbol/VOR">VOR</a> with an ‘Overweight’ rating and set a price target of $43. The firm said that it views VOR’s telitacicept, a recombinant fusion protein that is intended to treat autoimmune diseases, as "highly de-risked" across a range of indications.&nbsp;<h2 class="st-heading-2">Tapping Market Gaps</h2>JPMorgan’s coverage comes amid the pharma company’s success in its autoimmune disease treatment plans. In its latest quarterly results, VOR noted that telitacicept has “demonstrated consistent results on multiple efficacy endpoints, durable benefit, and a favorable safety profile”.&nbsp;VOR has a "significant valuation disconnect", JPMorgan said in its note, highlighting the probability-adjusted value of telitacicept to treat chronic conditions of myasthenia gravis and primary Sjogren's disease alone. The firm added that VOR, while focused on global indications that are less competitive, still has an unmet need that is significant.&nbsp;In other news, Vor Biopharma&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.vorbio.com/news-releases/news-release-details/vor-bio-announces-pricing-public-offering-100-million-common">announced</a> a $100 million public offering of common stock priced at $10 per share in November.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around VOR jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:1286/155;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_09_at_6_11_06_PM_png_fd2a6ad6c4.webp" alt="On Stocktwits, retail sentiment around VOR jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘extremely high’ levels." width="1286" height="155"></figure>One user on the platform predicted that VOR’s share price could go up to $20. The stock was trading around $10 at the time of writing.&nbsp;<a href="https://stocktwits.com/apux/message/638580684">https://stocktwits.com/apux/message/638580684</a>Shares of VOR have fallen almost 60% in the past one year.For updates and corrections, email newsroom[at]stocktwits[dot]com&nbsp;

Young female scientist working in laboratory (Representative image courtesy of Solskin via Getty Images)

VOR Shares Rally Over 40% In Pre-Market Trade After JPMorgan Initiates Bullish Coverage 

The firm gave Vor Biopharma an ‘Overweight’ rating with a price target of $43. 

VOR Shares Rally Over 40%In Pre-Market Trade After JPMorgan Initiates Bullish Coverage 

Equity

The firm gave Vor Biopharma an ‘Overweight’ rating with a price target of $43. 


<ul class="summary-bullets"><li>All eyes are on the Fed’s rate decision scheduled for Wednesday.&nbsp;</li><li>NVIDIA is in the spotlight after President Donald Trump declared on Monday that the U.S. will allow it to ship its H200 chips to China and other countries upon fulfillment of certain conditions, even as reports emerge of Beijing limiting access.</li><li>Retail sentiment on Stocktwits for the S&amp;P 500 ETF and Invesco QQQ was in the ‘bearish’ territory.</li></ul>U.S. equities are treading cautiously in Tuesday’s premarket session as investors await the Fed’s key rate policy decision due on Wednesday.While Dow Jones futures were up by 0.11% at the time of writing, the S&amp;P 500 futures rose 0.04% while the Nasdaq 100 futures declined 0.03%.&nbsp;The&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF</a> (SPY) was up by 0.06%,&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust</a> (QQQ) edged 0.03% lower, and&nbsp;<a href="https://stocktwits.com/symbol/DIA">SPDR Dow Jones Industrial Average ETF Trust</a> (DIA) rose 0.11% in premarket. Retail sentiment around the S&amp;P 500 ETF and Invesco QQQ on Stocktwits was in the ‘bearish’ territory.<h2 class="st-heading-2">Fed Rate Anticipation</h2>While the market expects a 25-basis-point cut, uncertainty about fresh tariffs on Mexico, Canada, and India is also affecting investor sentiment.&nbsp;There is an 89.4% probability of a 25 basis point rate cut this week, according to the latest data from the&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">CME FedWatch</a> tool. Last week, Morgan Stanley joined peers JPMorgan and Bank of America (BofA) to revise its expectations and reiterate a 25-basis-point cut from its previous expectation of a status quo policy.<h2 class="st-heading-2">Stocks To Watch</h2>Nvidia (NVDA): The chip giant is in the spotlight after President Donald Trump declared on Monday that the U.S. will allow it to ship its H200 chips to China and other countries upon fulfillment of certain conditions, even as reports emerge of Beijing limiting access. Shares of&nbsp;<a href="https://stocktwits.com/symbol/NVDA">NVDA</a> are up 1.7% in premarket trading.Vor Biopharma (VOR):&nbsp;<a href="https://stocktwits.com/symbol/VOR">VOR shares</a> are up over 26% at the time of writing due to positive sentiment around a recent Phase 3 clinical study. JPMorgan has initiated coverage on Vor Bio with a bullish view.Exicure Inc (XCUR): The early-stage biotech company&nbsp;<a href="https://stocktwits.com/symbol/XCUR">XCUR</a> is up over 77% in premarket trading because of positive Phase 2 trial results for its cancer treatment.GameStop (GME), Dave &amp; Buster's (PLAY), Core &amp; Main Inc (CNM), SailPoint Technologies (SAIL), and Casey's General Stores (CASY) are among the companies scheduled to report their latest quarterly earnings on Tuesday.For updates and corrections, email newsroom[at]stocktwits[dot]com.

The New York Stock Exchange (NYSE) stands off Wall Street on April 17, 2025 in New York City. (Photo by Spencer Platt/Getty Images)

Futures Tread Cautiously Pre-Market As Investors Await Key Fed Decision: NVDA, XCUR, GME, CASY Among Stocks To Watch

The Dow Jones futures were up by 0.11% while the S&P 500 futures were up 0.04%. 

Vor Biopharma Inc. (NASDAQ:VOR) Receives Consensus Recommendation of "Hold" from Brokerages

Vor Biopharma Inc. (NASDAQ:VOR - Get Free Report) has been given a consensus rating of "Hold" by the eleven ratings firms that are presently covering the company, MarketBeat Ratings reports. One...

Wedbush Predicts Vor Biopharma's Q4 Earnings (NASDAQ:VOR)

Vor Biopharma Inc. (NASDAQ:VOR - Free Report) - Research analysts at Wedbush issued their Q4 2025 EPS estimates for shares of Vor Biopharma in a research note issued to investors on Tuesday, November...

Wedbush Initiates Coverage on Vor Biopharma (NASDAQ:VOR)

Wedbush restated a "neutral" rating and issued a $9.00 price target on shares of Vor Biopharma in a research note on Tuesday...

Vor Biopharma (VOR) Upgraded to Buy: Here's What You Should Know

Vor Biopharma (VOR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Vor Biopharma (NASDAQ:VOR) Posts Quarterly Earnings Results, Misses Expectations By $0.27 EPS

Vor Biopharma (NASDAQ:VOR - Get Free Report) announced its earnings results on Thursday. The company reported ($3.33) earnings per share (EPS) for the quarter, missing analysts' consensus estimates...

VOR
Vor Biopharma Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest VOR News

VORVor Biopharma Inc